Lilly To Pay Up To $755M For Autoimmune Treatments

Law360, New York (December 22, 2009, 4:15 PM EST) -- Eli Lilly & Co. has agreed to purchase the rights to anti-inflammatory and autoimmune treatments from Incyte Corp. for up to $755 million, the companies have announced.

Lilly will make an initial payment of $90 million, and pay Incyte up to $665 million in possible future milestones, in addition to future royalties and sales payments if the products are successfully commercialized, according to a joint statement issued Monday.

The Indianapolis-based pharmaceutical giant will receive worldwide rights to develop and commercialize Incyte's oral therapies being developed for...
To view the full article, register now.